NanoSphere Health Sciences To Report Revenue and Sees Significant Sales Growth in Second Quarter

Biotech leader increases cannabis brand sales in Colorado by 30 percent ahead of California launch

DENVER (July 4, 2018)– NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), the biotech firm behind the cutting-edge patented NanoSphere Delivery System™ and the cannabis brand Evolve Formulas, today reports solid growth for this year’s second quarter.

The company has exceeded growth projections, experiencing rapid expansion and demonstrating unprecedented success since its inception in 2013. After four years of R&D, NanoSphere Health released the first of its Evolve Formulas cannabis products in January 2018, utilizing the NanoSphere Delivery System™ in order to nanoencapsulate cannabis molecules for transportation through the skin into systemic circulation within minutes.

The pioneering product, Transdermal NanoSerum™, is now stocked in approximately 200 dispensaries in Colorado and saw over 3,400 units sold in June 2018 – a rise of 35 percent in sales from May, showing the increasing popularity of this first and only standardized delivery system for cannabis, which studies show increases bioavailability of the drug, eliminates adverse side effects and significantly reduces delayed onset of action.

NanoSphere Health Sciences recently entered into a partnership with Vertical™ - the largest fully integrated company in the legal medical cannabis industry - in order to bring Evolve Formulas products to California and Arizona through licensing IP for the NanoSphere Delivery System™. Production of Evolve Formulas products in California and sale of the products through dispensaries is expected to begin in late August 2018.

These growth factors, along with the continuous momentum propelled by numerous awards, multiple patents and new product releases have led to significant revenue for the company in the second quarter of 2018.

“NanoSphere Health Science’s tremendous growth in the second quarter of 2018 is evident through boosted sales, the enthusiastic public reception of new Evolve Formulas products and acknowledgement of the unique science we bring to the world of nanotechnology and cannabis delivery. Our continued financial success is a reflection of our team's dedication to vastly improving medical delivery across sectors. The NanoSphere Delivery System™ is the innovation that so many healthcare professionals and patients are looking for to change their lives, and these accomplishments inspire us to work even harder toward making the cutting-edge products more broadly available,” said Robert Sutton, Chairman, CEO and co-founder of NanoSphere Health Sciences and Evolve Formulas

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 702-957-6203.

###

On behalf of the Board
Robert Sutton, Chairman and CEO
Office: 720-520-4282
Email: rsutton@nanospherehealth.com

Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Samuel TheilComment